Homeward Health vs Becton Dickinson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Minneapolis value-based care company delivering primary care to rural Americans via in-home visits and telehealth; targets provider-shortage areas where patients face long distances to care.
About
Homeward Health is a Minneapolis-based healthcare company that provides primary care and chronic disease management to rural populations who lack access to local providers, using a hybrid model combining in-home clinical visits, telehealth, and community-based care navigators. Rural Americans face significantly worse health outcomes than urban populations due to provider shortages, long travel distances to care, and lower rates of insurance coverage. Homeward deploys care teams that travel to rural areas to see patients in their homes and community settings, supplemented by telehealth for follow-up and specialist access, creating continuity of care that most rural residents cannot access. The company operates under value-based care contracts that align incentives around keeping patients healthy and out of the hospital rather than fee-for-service volume. Founded in 2021, Homeward raised over $50M from investors including General Catalyst, Tiger Global, and Andreessen Horowitz Bio. The company targets the significant rural health gap and the growing population of Medicare Advantage plans seeking to improve outcomes and reduce costs for rural beneficiaries.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
About
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.